Continuous Glucose Monitoring Following Hospital Discharge

Kathleen Dungan

Status: Active, not recruiting

Conditions: Type 2 Diabetes

Treatments: Device: DexCom G6

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05360056

2021H0426

Details and patient eligibility

About

In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Enrollment: 108 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 Diabetes
• Basal insulin use >10 units per day
• Hemoglobin A1c >8.0%
• Smartphone compatible with Clarity App
• Age ≥18 years

Exclusion criteria

• Type 1 DM
• Inability to consent
• Pregnancy
• Prisoners
• Discharge to skilled nursing facility

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

108 participants in 1 patient group

Dexcom CGM

Experimental group

Treatment:

Device: DexCom G6